Predictive Oncology to Delist from NASDAQ by Investing.com

PITTSBURGH, PA – Predictive Oncology Inc. (NASDAQ:POAI), a medical device company with a mid-market share of orthopedic, prosthetic and surgical devices and specialty equipment, is spreading its drug action to the bones of the mind.

On 19.09.2024, when the tribe of the Unternehmens had a 30-year-old schäftstagen under 1.00 US-Dollar pro Action geschlossen, was not the Anforderungen of the NASDAQ for a fortgesetzte notierung-spricht.

The current situation may cause an indefinite situation in the notification of the master accounts of the external systems. Predictive Oncology has 180 calendar days, also until 18.03.2025, time, in order to again fulfill the NASDAQ’s Mindstangebotspreisreassurance request.

The e-inhalation can be completed if the company’s shares are sold and 10 other steps are taken to close the foundation to an amount of more than US$1.00 for the agreement.

If the company does not pass the Mindestangebotspreisapproval until 18.03.2025, it could come into question for an extension. If you qualify for the qualification, Predictive Oncology must be all others who inherit the knowledge on the NASDAQ Capital Market, with the extended bone distribution, and the NASDAQ must make a plan for the information about the Mangels, which may be split by a number of large actions.

Predictive Oncology is no longer at the heart of the times and is no longer an extension of the question, while the NASDAQ is informed by the American business community that its trading papers will be published off the stock exchange.

The people from abroad have the possibility to eliminate the separation reactions. There is no guarantee that you will get a very good guarantee for a strengthened notification of the würde.

In others, the Predictive Oncology financial analysis for the second quarter of 2024 has started with sales from US$490,000 to US$279,000 in the quarter of Vorjahres. If you take out a loan, you can reduce a Net Excess for Action from US$0.98 to US$0.68. Brands are aware of one of the affiliated Eierstock Krebs studies with UPMC Magee-Womens Hospital and have developed a 3D-Zellkultur technology.

Ensure that the best predictive oncology studies stabilize the long-term stability of patients’ cancer therapies and tumor studies in the Biobank, a separate aspect of patient treatment and personalization of therapies. The study has achieved a 100% high immunity rate through the testing of fresh patients and the cryogenically stored material, increasing the amount of years brought to attention.

Darüber is focused on Predictive Oncology, a research area that explores the intelligence and machine learning capabilities of biomarker research and the cost savings that funding the Pittsburgh operations enables.

We are proud to have a business relationship with a cumulative deposit of 175 million US dollars and receive 5 million US dollars capital and receive net cash for the final month until 30 June 2024 with 6.6 million US dollars sent.

This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.